GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs) | ENROLLING NOW
Menu
GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs) | ENROLLING NOW
For more information about the Gestalt Trial, please email us at clinicalaffairs@gtmedtech.com
To locate the nearest enrolling site for you, refer to the participating hospital map
The GESTALT Trial is sponsored by GT Medical Technologies, Inc., the makers of GammaTile®. Please discuss the risks and benefits of participating in this clinical trial with your care team.
Indication: GammaTile is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.
Safety Information: The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). GammaTile should not be used for patients with a known history of hypersensitivity to bovine-derived materials.
GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs)
©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.